Lipid-lowering drugs: present and future
- Authors: Selizarova N.O.1, Napalkova S.M.1, Anisimova N.A.1, Buyuklinskaya O.V.1, Bolotova V.T.1, Okovityi S.V.1
-
Affiliations:
- Saint Petersburg State Chemical-Pharmaceutical University
- Issue: Vol 22, No 4 (2024)
- Pages: 411-424
- Section: Lectures
- URL: https://journal-vniispk.ru/RCF/article/view/283525
- DOI: https://doi.org/10.17816/RCF632629
- ID: 283525
Cite item
Abstract
Hyperlipidemia is one of the most important risk factors for the development atherosclerotic cardiovascular diseases. The review summarizes data on lipoprotein metabolism and discusses methods pharmacological correction of dyslipidemia. Classification presented Lipid-lowering drugs, pharmacodynamics and pharmacokinetic features, indications for use and side effects of individual representatives, issues of their effectiveness and safety are considered. Prospects for the treatment of dyslipidemia are outlined.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Natalia O. Selizarova
Saint Petersburg State Chemical-Pharmaceutical University
Author for correspondence.
Email: natalia.selizarova@pharminnotech.com
ORCID iD: 0000-0003-4826-2416
SPIN-code: 6415-5003
MD, Cand. Sci. (Medicine)
Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376Svetlana M. Napalkova
Saint Petersburg State Chemical-Pharmaceutical University
Email: svetlana.napalkova@pharminnotech.com
ORCID iD: 0000-0002-9216-8673
SPIN-code: 7311-2841
Dr. Sci. (Biology), Professor
Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376Natalia A. Anisimova
Saint Petersburg State Chemical-Pharmaceutical University
Email: natalia.anisimova@pharminnotech.com
ORCID iD: 0000-0002-2620-2976
SPIN-code: 8747-6166
Cand. Sci. (Biology), Assistant Professor
Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376Olga V. Buyuklinskaya
Saint Petersburg State Chemical-Pharmaceutical University
Email: olga.buyklinskaya@pharminnotech.com
ORCID iD: 0000-0002-4453-1079
SPIN-code: 9691-6490
MD, Dr. Sci. (Medicine), Assistant Professor
Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376Vera Ts. Bolotova
Saint Petersburg State Chemical-Pharmaceutical University
Email: vera.bolotova@pharminnotech.com
ORCID iD: 0000-0001-7559-186X
SPIN-code: 5035-2066
Cand. Sci. (Pharmacy), Assistant Professor
Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376Sergey V. Okovityi
Saint Petersburg State Chemical-Pharmaceutical University
Email: sergey.okovity@pharminnotech.com
ORCID iD: 0000-0003-4294-5531
SPIN-code: 7922-6882
Dr. Sci. (Medicine), Professor
Russian Federation, 14, litera A Professora Popova st., Saint Petersburg, 197376References
- Oksenoit GK, Nikitin SY, editors. Health care in Russia. Statistical collection. Moscow: Rosstat; 2017. 170 p. (In Russ.)
- Sergienko IV, Nedogoda CV, Vertkin AL, et al. Actual issues of increasing the availability of innovative therapy and organization of medical care for patients with atherosclerotic cardiovascular diseases in the Russian Federation. Council of experts. Journal of Atherosclerosis and Dyslipidemias. 2022;(49):54–61. (In Russ.) EDN: CVUPPX doi: 10.34687/2219-8202.JAD.2022.04.0006
- Golan DE, Armstrong EJ, Armstrong AW, editors. Principles of pharmacology: the pathophysiologic basis of drug therapy: fourth Edition. Elsevier: 2017. P. 1042.
- Chaulin AM. New groups of hypolipidemic medications based on inhibition of proprotein convertase subtilisin/kexin type 9 (pcsk9). Part 1. Clinical Medicine. 2020;98(11–12):739–744. EDN: JXHPIA doi: 10.30629/0023-2149-2020-98-11-12-12-739-744
- Borodulin VI, Topoliansky AV. To the scientific results of the twentieth century: the role of domestic researchers in the development of atherosclerosis. Clinical Medicine. 2013;91(11):70–73. (In Russ.) EDN: RSHRUP
- Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5
- Karpov YuA. The efficacy and safety of statin therapy. Atmosphere. Cardiology News. 2019;(1):3–12. EDN: GRIGYR
- Chaulin AM. The main side effects of statins in clinical practice. Clinical Practice. 2022;13(2):98–107. EDN: QHSXST doi: 10.17816/clinpract108076
- Makhatova AR, Tuleutaeva RE. Dangerous and undesirable drug interactions of statins in patients with cardiovascular disease. Science & Health Care. 2019;21(2):55–56. EDN: ZKVNBB
- Sumarokov AB, Kukharchuk VV. Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia. Therapeutic Archive. 2014;86(12): 107–115. EDN: RNYIIS doi: 10.17116/terarkh20148612107-115
- Lawitz EJ, Bhandari BR, Ruane PJ, et al. Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin Gastroenterol Hepatol. 2023;21(1): 143–152.e3. doi: 10.1016/j.cgh.2021.12.044
- Shaposhkin AI, Genkel VV. Pleiotropic effects of ezetimibe. Cardiology. 2019;59(12):12–17. EDN: ZIIFEL doi: 10.18087/cardio.n875
- Gurevich VS, Solodovnikov AG, Manko KS, et al. The efficacy of ezetimibe and statin combination therapy compared to statin monotherapy: a systematic review and meta-analysis of observational trials. Atmosphere. Cardiology News. 2023;(3):33–46. EDN: PFTAPH doi: 10.24412/2076-4189-2023-13015
- Robinson JG, Rogers WJ, Nedergaard BS, et al. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014;37(4):195–203. doi: 10.1002/clc.22252
- Schneider KO, Maksimov ML, Baranova VA, et al. PCSK9 inhibitor therapy as an alternative for statin intolerance. Safety and Risk of Pharmacotherapy. 2023;11(4):442–449. EDN: OZZYFX doi: 10.30895/2312-7821-2023-366
- Vatutin NT, Taradin GG, Rakitskaya IV, et al. Hypolipidemic therapy in insufficient efficacy or intolerance of statins (literature review). Bulletin of Emergency and Restorative Therapy. 2020;5(4):29–39. EDN: VPAHIT
- O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109–1119. doi: 10.1161/CIRCULATIONAHA.122.061620
- Santos RD, Ruzza A, Hovingh GK, et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022;10(10):732–740. doi: 10.1016/S2213-8587(22)00221-2
- Ezhov MV, Kukharchuk VV. Disorders of lipid metabolism. Clinical guidelines 2023. Russian Cardiology Journal. 2023;28(5):54–71. EDN: YVZOWJ doi: 10.15829/1560-4071-2023-5471
- Voyevoda MI, Gurevich VS, Ezhov MV, et al. Inclisiran — a new era in lipid-lowering therapy. Cardiology. 2022;62(6):57–62. EDN: NEWLUX doi: 10.18087/cardio.2022.6.n2115
- Jain P. Traditional and novel non-statin lipid-lowering drugs. Indian Heart J. 2024;76(Suppl 1):S38–S43. doi: 10.1016/j.ihj.2023.11.003
- Petrosyan AS, Rud RS, Polyakov PP, et al. The pathogenetic basis of the action of bempedoic acid. Rational Pharmacotherapy in Cardiology. 2022;18(6):734–741. EDN: HLENQU doi: 10.20996/1819-6446-2022-12
- Tummala R, Gupta M, Devanabanda AR, et al. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis. Annals of Medicine. 2022;54(1):1287–1296. EDN: RAOOHE doi: 10.1080/07853890.2022.2059559
- Banach M, Duell PB, Gotto AM Jr, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5(10):1124–1135. doi: 10.1001/jamacardio.2020.2314
- Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–1032. doi: 10.1056/NEJMoa1803917
